Analysis of the immunological pathogenesis of the seronegative autoimmune diseases

Japanese Journal of Clinical Immunology

Volumn 25, Issue 4, 2002, Pages 302-309

  Shinomiya, Noriaki ^a  

^a TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

Author keywords

HLA DQ allele; latent general type; myasthenia gravis; seronegative autoimmune disease; T cell receptor

Indexed keywords

CHOLINERGIC RECEPTOR; HLA DQ ANTIGEN; HLA DR ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; LYMPHOKINE;

ALLELE; ANIMAL; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; GENETIC POLYMORPHISM; GENETICS; HAPLOTYPE; HUMAN; IMMUNOLOGY; REVIEW;

ALLELES; ANIMALS; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; HAPLOTYPES; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; LYMPHOKINES; POLYMORPHISM, GENETIC; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, CHOLINERGIC;

EID: 1542344724     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.25.302     Document Type: Article

References (24)

1. Drachman, D.B.: Myasthenia gravis. N. Engl. J. Med. 330: 1797–1810, 1994.
2. Shinomiya, N., Shinomiya, M., Nomura, Y., Segawa, M.: Analysis of HLA-DPB 1 allele associated with childhood-onset myasthenia gravis. J. Med. Soci. Toho 43: 473—483, 1997.
3. Oda, K., Ito, Y.: Myasthenia gravis: antibodies to acetylcholine receptor in ocular myasthenia gravis. J. Neurol. 225: 251—253, 1981.
4. McDevitt, H.O.: The role of MHC class II molecules in susceptibility and resistance to autoimmunity. Curr. Opin. Immunol. 10: 677-681, 1998.
5. O’Garra, A., Steinman, L., Gijbels, K.: CD4 + T-cell subsets in autoimmunity. Curr. Opin. Immunol. 9: 872—883, 1997.
6. Matsuki, K., Juji, T., Tokunaga, K., et al.: HLA antigens in Japanese patients with myasthenia gravis. J. Clin. Invest. 86: 392—399, 1990.
7. Hawkins, B.R., Yu, Y.L., Wong, V., Woo, E., Dawkins, R.L.: Possible evidence for a variant of myasthenia gravis based on HLA and acetylcholine receptor antibody in Chinese patients., Q.J. Med. 70: 235—241, 1989.
8. Carlsson, B., Wallin, J., Pirskanen, R., Matell, G., et al.: Different HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis. Immunogenetics 31: 285—290, 1990.
9. Tiwari, J.L., Terasaki, P.I.: HLA and Disease association. Springer-Verlag New York. pp 472—475, 1985.
10. Oen, K., Schroeder, M., Jacobson, K., et al.: Juvenile rheumatoid arthritis in a Canadian First Nations (aboriginal) population: onset subtypes and HLA association. J. Rheumatol. 25: 783—790, 1998.
11. Sugihara, S., Sakamaki, T., Konda, S., Murata, A., et al.: Association of HLA-DR, DQ genotype with different beta-cell functions at IDDM diagnosis in Japanese. Diabetes 46: 1893–1897, 1997.
12. Balasa, B., Sarvetnick, N.: Is pathogenic humoral autoimmunity a Th 1 response? Lessons from (for) myasthenia gravis. Immunol. Today 21: 19—23, 2000.
13. Zang, G-X., Xia, B-G., Bai, X-F., van Der Meide, P.H., et al.: Mice with IFN-y receptor deficiency are less susceptibile to experimental autoimmune myasthenia gravis. J. Immunol. 162: 3775—3782, 1999.
14. Kanai, T., Nomura, Y., Segawa, M., Takagi, K., et al.: Immuno-suppressive peptides for a human T cell clone autoreactive to a unique acetylcholine receptor alpha subunit peptide presented by disease-susceptible HLA-DQ 6 in infant onset myasthenia gravis. Human Immunol. 56: 28—38, 1997.
15. Del Preter, G.F., Tiri, A., De Carli, M., Mariotti, S., et al.: Cytotoxic T cells with Th 1-like cytokine profile predominant in retroorbital lymphocyte infiltrates of Graves’opthalmopathy. J. Clin. Endocrin. Metab. 77: 1120-1124, 1993.
16. Wucherpfenning, K.W., Strominger, J.L.: Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune disease. J. Exp. Med. 181: 1597–1601, 1995.
17. Nishimura, Y., Oiso, M., Fujisao, S., Kanai, T., et al.: Peptide-based molecular analyses of HLA class II-associated susceptibility to autoimmune disease. Int. Rev. Imunol. 17: 229—242, 1998.
18. Shinomiya, N., Shinomiya, M., Nomura, Y., Segawa, M.: Polymorphic amino residues in the HLA-DQ molecule are associated with disease heterogeneity in childhood-onset myasthenia gravis in Japan. J. Med. Soci. Toho 47: 390–398, 2000.
19. Hjelmstrom, P., Giscombe, R., Lefvert, A.K., et al.: Polymorphic amino acid domains of the HLA-DQ molecule are associated with disease hetergenity in myasthenia gravis. J. Neuroimmunol. 65: 125—131, 1996.
20. Raju, R., Zhan, W-Z., Karachunski, P., Conti-Fine, B., et al.: Polymorphism at the HLA-DQ locus determines susceptibility to experimental autoimmune myasthenia gravis. J. Immunol. 160: 4169—4174, 1997.
21. Davis, M.M., Boniface, J.J., Reich, Z., Lyons, D., et al.: Ligand recognition by alpha beta T cell receptors. Annu. Rev. Immunol. 16: 523-544, 1998.
22. Cochran, J.R., Cameron, T.O., Sterm, L.J.: The relationship of MHC-peptide binding and T cell activation probed using chemically defined MHC class II oligomers. Immunity 12: 241—250, 2000.
23. Conti-Fine, B.M., Wang, Z-Y., Raju, R., Howard Jr, J.F., et al.: Anti-acetylcholine receptor CD4 + T cells in myasthenia gravis: epitope repertoire and T cell receptor gene usage. Myastenia Gravis: Disease mechanisms and immunointervention, Christadoss (Ed), Narosa Publishing House, New Delhi, pp 73—93, 2000.
24. Wang, Z-Y., Okita, D.K. Howard Jr, J.F., Conti-Fine, B.M.: Th 1 epitope repatoire on the a subunit of human muscle acetylcholine receptor in myasthenia gravis. Neurology 48: 1643–1653, 1997.